Novel Myopia Control Contact Lens Performs Comparably With Established Design

Two novel myopia control contact lenses (DT and F2) that use spatio-temporal optical phase (STOP) technology demonstrate comparable visual performance and binocular and accommodative function with MiSight® lenses — the only US Food and Drug Administration (FDA) approved contact lenses for myopia management, according to a study published in Eye & Contact Lens.

Researchers included 28 patients with myopia (67.9% women; mean age, 27 years) in the prospective, randomized, single-masked, cross-over study. A total of  27 participants wore both the MiSight® and F2 designs, while 28 wore the DT lens. Lenses were worn daily for 7 days and cleaned with hydrogen peroxide overnight.

Participants subjectively reported clarity of vision, lack of ghosting, vision when driving and overall vision satisfaction using a non validated scale (0, poor; 100, excellent). The research team evaluated monocular high and low-contrast visual acuity, accommodative function, and dynamic monocular accommodative response.

Patients report that the F2 design was superior to MiSight® for clarity of vision (intermediate, 71 vs 61; near, 78 vs 64; P <.001 for both). MiSight®, however, received higher ratings compared with the DT design for clarity of vision (near, 64 vs 56; P <.001). 

MiSight® outperformed both the F2 and DT lenses with respect to monocular (6m) and binocular high-contrast visual acuity HCVA (6 m and 40 cm, P ≤.02 for both), but the maximum difference was 2 letters or less. 

 The F2 design had a higher monocular accommodative facility (P =.007) and a lower accommodative response (70cm and 40 cm; P ≤.007) compared with MiSight® lenses.

Overall, researchers could not conclusively assert that 1 lens design was superior to another. “The dynamic optical cue provided by S.T.O.P. designs F2 and DT shows comparable visual performance and binocular/accommodative function compared with the static optical cue provided by the MiSight design,” the study authors note.

Study limitations include the reuse of the single use MiSight® lenses and the use of a non validated questionnaire.

Disclosure: This research was supported by Brighten Optix Corporation and nthalmic Pty Ltd. Multiple study authors declared affiliations with biotech, pharmaceutical, and/or clinical research organizations. Please see the original reference for a full list of authors’ disclosures.